Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 27, 2015 4:54 AM ET


Company Overview of Agila Specialties Private Limited

Company Overview

Agila Specialties Private Limited manufactures and markets pharmaceutical products. The company offers penicillin, cephalosporins, peptides, oncology drugs, and sterile injectables. The company was formerly known as Strides Specialties Pvt Ltd. and changed its name to Agila Specialties Private Limited in November, 2010. The company was incorporated in 2004 and is based in Bengaluru, India. As of December 4, 2013, Agila Specialties Private Limited operates as a subsidiary of Mylan, Inc.

Strides House


Opposite IIM

Bannerghatta Road

Bengaluru,  560076


Founded in 2004


91 80 6784 0000


91 80 6784 0800

Key Executives for Agila Specialties Private Limited

Chief Executive Officer
Compensation as of Fiscal Year 2014.

Agila Specialties Private Limited Key Developments

Agila Specialties Private Limited Initiates Voluntary Nationwide Recall of 10 Lots of Etomidate Injection 2 Mg/Ml - 10 Ml and 20 Ml

Mylan Inc. announced that its subsidiary Agila Specialties Private Limited is conducting a voluntary nationwide recall to the hospital/user level of 10 lots of Etomidate Injection 2 mg/mL -10 mL and 20 mL. The 10 lots were manufactured by Agila Specialties Polska sp.zo.o in Warsaw, Poland. All of the products bear a Pfizer label. Agila Specialties Private Limited initiated the recall on Feb. 13, 2014, due to the potential for small black particles, identified as paper shipper labels, to be present in individual vials; the potential for missing lot number and/or expiry date on the outer carton, and the potential for illegible/missing lot number and expiry on individual vials. Intravenous administration of particles may lead to impairment of microcirculation, phlebitis, infection, embolism and subsequent infarction. Mylan and Pfizer have not received any reports of adverse events related to the recalled product to date. Etomidate is a hypnotic drug without analgesic activity. It is indicated by intravenous injection for the induction of general anesthesia. Etomidate is also indicated for the supplementation of subpotent anesthetic agents. Etomidate 2 mg/mL is packaged in glass vials in 10 mL and 20 mL volumes. Product was distributed Nationwide to distributors, retailers, hospitals, pharmacies, and/or clinics. Mylan notified its customers of the recall by letter on Feb. 13, 2014. Distributors, retailers, hospitals, pharmacies, or clinics that have product which is being recalled should stop use and discontinue distribution.

Similar Private Companies By Industry

Company Name Region
Aristo Pharmaceuticals Pvt. Ltd. Asia
Sphaera Pharma Pvt. Ltd. Asia
Nirayu Pvt. Ltd. Asia
Colorcon Asia Private Limited Asia
Doctors Organic Chemicals Ltd. Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Agila Specialties Private Limited, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at